Current Therapeutic Strategies in BRAF|Mutant Metastatic ...

Current Therapeutic Strategies in BRAF-Mutant Metastatic ... - PubMed

Around 8-12% of patients with advanced colon rectal cancer (CRC) present with BRAF alterations, in particular V600E mutation, ...

Current Therapeutic Strategies in BRAF-Mutant Metastatic ... - Frontiers

The focus of this review is to summarize current strategies for BRAF-mt CRC treatment and highlight new therapeutic options.

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing ...

On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAFV600E-mutated metastatic colorectal cancer include first-line ...

Treatment of patients with BRAF V600E -mutated metastatic ...

Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer ( ...

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence ...

Improved understanding of the biology of the BRAF oncogene has led to the development of targeted therapies that have paved the way for a paradigm shift in ...

Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer - EMJ

Combination therapy with encorafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, has become the standard of care for patients with ...

Treatment Options in BRAF-mutant Metastatic Colorectal Cancer

Recently, the development of BRAF V600E inhibitors has expanded the therapeutic armamentarium, although exclusive targeting of BRAF has proved ...

The Evolving Treatment Landscape in BRAF-V600E–Mutated ...

Novel approaches for managing BRAF-V600E metastatic colorectal cancer include combinations of BRAF inhibitors and anti-EGFR antibodies with immune checkpoint ...

Management of BRAF-mutant metastatic colorectal cancer: a review ...

The current standard therapies for first-line treatment of BRAF-mutated mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, ...

Management of BRAF Gene Alterations in Metastatic Colorectal ...

There is no specific regimen recommended for first-line therapy of BRAF-mutated tumors, as the National Comprehensive Cancer Network guidelines ...

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal ...

It doesn't work well as a single agent in colorectal cancer vs other cancers. We have to combine it with anti-EGFR therapy, and encorafenib is ...

Immune checkpoint blockade therapy for BRAF mutant metastatic ...

Although screening strategies effectively reduce mortality and morbidity from CRC [2], approximately 20–35% of CRC patients have distant ...

European expert panel consensus on the clinical management of ...

Currently, ESMO clinical practice guidelines recommend doublet chemotherapy ± bevacizumab as first-line treatment in patients with BRAFV600E-mutant mCRC and ...

Exploring the best treatment options for BRAF-mutant metastatic ...

In this review, we highlight still-emerging strategies that could be deployed to combat BRAF-mt mCRC, including triplet chemotherapy plus available biologic ...

New therapeutic strategies for BRAF mutant colorectal cancers

In early 2014, dabrafenib and trametinib in combination received accelerated FDA approval for metastatic or unresectable BRAF mutant melanoma. Given the success ...

Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal ...

I don't think we've actually said it out loud, but if someone has a concurrent BRAF mutation and they are MSI-high, we recommend immunotherapy ...

BRAF Mutations in Colorectal Liver Metastases - MDPI

The regimen of dabrafenib + trametinib + cetuximab can be used as an alternative treatment and can improve overall and progression-free survival. Clinical ...

Targeting BRAF V600E in metastatic colorectal cancer - ecancer

Immunotherapy has been evaluated as an alternative treatment in mCRC in clinical trials that included patients with BRAF mutation. The Keynote-164 trial (N = ...

Current Therapeutic Strategies in BRAF-Mutant Metastatic ... - OUCI

Currently, the standard of care is an aggressive strategy involving triplet chemotherapy and anti-VEGF agents, but new therapeutic approaches are emerging. Very ...

Combined targeted therapy for BRAF mutant metastatic colorectal ...

Therefore, encorafenib might just be the most appropriate BRAF inhibitor currently available for application in combination with EGFR inhibition ...